David Liu

Hidden away in our voices are signals that may hold clues to how we’re doing, what we’re feeling and even what’s going on with our physical health. Now, AI systems tasked with analyzing these signals are moving into healthcare.We meet:Lina Lakoczky-Torres, student at Menlo CollegeAngela Schmiede, Vice President of Menlo College.Grace Chang, CEO of KintsugiDavid Liu, CEO of Sonde HealthLiam Kaufman, former CEO of Winterlight Labs. Margaret Mitchell, Chief Ethics Scientist of Hugging FaceBjoern Schuller, professor of artificial intelligence at Imperial College LondonCredits:This episode was reported by Hilke Schellmann, produced by Jennifer Strong, Emma Cillekens and Anthony Green, edited by Mat Honan and mixed by Garret Lang with original music by Garret Lang and Jacob Gorski. Artwork by Stephanie Arnett. Special thanks to the Knight Science folks at MIT for their support with this reporting. 

David Liu, VP of Strategy for Pinduoduo, discusses how PDD succeeded in China's e-commerce market, defied expectations in raising capital and user growth. The podcast explores Pinduoduo's unique business model, C2M strategy, expanding footprint, restricted cash significance, seven-day return policy, and competition in the Chinese e-commerce market.

Former U.S. Secretary of State John Kerry shares his insights on climate change and international relations, contrasting Biden's and Trump's approaches to policy. Bestselling author Laura Bates discusses the unsettling intersections of AI and misogyny, highlighting the dangers of digital abuse. Biochemist David Liu elaborates on groundbreaking gene editing technologies that promise revolutionary healthcare advancements. Together, they delve into the pressing ethical and practical challenges of today's fast-evolving scientific landscape.

Professor David Liu, co-founder of biotech companies, discusses cutting-edge gene editing technologies like CRISPR Cas9 and prime editing. He shares insights on his journey from childhood curiosity to revolutionizing the biotech industry, highlighting the potential of CRISPR technology in treating diseases like sickle cell anemia and beta thalassemia.

Molecular biologist David Liu discusses advancements in genome editing beyond CRISPR, including delivery into cells and ethical dilemmas. The interview explores the significance of recent UK approval for genome editing and potential future applications in treating genetic disorders and altering genetic risk factors.